Improving olaparib exposure to optimize adverse effects management

CONCLUSION: Based on real-world data, we were able to properly describe the time course of haemoglobinaemia and plasma creatininaemia during olaparib treatment.PMID:38665845 | PMC:PMC11044803 | DOI:10.1177/17588359241248328

Source: Molecular Medicine - April 26, 2024 Category: Molecular Biology Authors: Marylise Sterl é Alicja Puszkiel Chlo é Burlot Eva Pereira Audrey Bellesoeur Sixtine De Percin Guillaume Beinse Jean-David Fumet Laure Favier Julie Niogret Benoit Blanchet Bernard Royer Le ïla Bengrine-Lefevre Antonin Schmitt Source Type: research